Your browser doesn't support javascript.
loading
Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study.
Zattoni, Fabio; Marra, Giancarlo; Martini, Alberto; Kasivisvanathan, Veeru; Grummet, Jeremy; Harkin, Timothy; Ploussard, Guillaume; Olivier, Jonathan; Chiu, Peter K; Valerio, Massimo; Marquis, Alessandro; Gontero, Paolo; Guo, Hongqian; Zhuang, Junlong; Frydenberg, Mark; Moon, Daniel; Morlacco, Alessandro; Kretschmer, Alexander; Barletta, Francesco; Heidegger, Isabel; Tilki, Derya; van den Bergh, Roderick; Dal Moro, Fabrizio; Briganti, Alberto; Montorsi, Francesco; Novara, Giacomo; Gandaglia, Giorgio.
Afiliação
  • Zattoni F; Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padova, Padova, Italy.
  • Marra G; Department of Urology, Institut Mutualiste Montsouris, Paris, France.
  • Martini A; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Kasivisvanathan V; Division of Surgery and Interventional Science, University College London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Grummet J; Department of Surgery, Monash University, Melbourne, Australia.
  • Harkin T; Department of Surgery, Monash University, Melbourne, Australia.
  • Ploussard G; Department of Urology, La Croix du Sud Hospital, Toulouse, France.
  • Olivier J; Department of Urology, Lille University, Lille, France.
  • Chiu PK; Division of Urology, Department of Surgery, The Chinese University of Hong Kong, Hong Kong.
  • Valerio M; Urology Department, Lausanne University Hospital, Lausanne, Switzerland.
  • Marquis A; University of Turin, Molinette Hospital, Turin, Italy.
  • Gontero P; University of Turin, Molinette Hospital, Turin, Italy.
  • Guo H; Department of Urology, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, People's Republic of China.
  • Zhuang J; Department of Urology, Nanjing Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, People's Republic of China.
  • Frydenberg M; Department of Surgery, Faculty of medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia; Cabrini Institute, Cabrini Health, Malvern, VIC, Australia.
  • Moon D; Royal Melbourne Clinical School, University of Melbourne, Melbourne, Australia; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Morlacco A; Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padova, Padova, Italy.
  • Kretschmer A; Department of Urology, University Hospital Munich, Campus Großhadern, Ludwig-Maximilians University, Munich, Germany.
  • Barletta F; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Heidegger I; Department of Urology, Medical University Innsbruck, Innsbruck, Austria.
  • Tilki D; Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Koc University Hospital, Istanbul, Turkey.
  • van den Bergh R; Department of Urology, St Antonius Hospital, Utrecht, The Netherlands.
  • Dal Moro F; Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padova, Padova, Italy.
  • Briganti A; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Montorsi F; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Novara G; Department Surgery, Oncology and Gastroenterology, Urologic Unit, University of Padova, Padova, Italy.
  • Gandaglia G; Unit of Urology/Division of Oncology, Gianfranco Soldera Prostate Cancer Laboratory, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Eur Urol Focus ; 9(4): 621-628, 2023 07.
Article em En | MEDLINE | ID: mdl-36746729
BACKGROUND: The concordance rates of transperineal (TP) versus transrectal (TR) prostate biopsies with radical prostatectomy (RP) specimen have been assessed poorly in men diagnosed with magnetic resonance imaging (MRI)-targeted biopsy (TBx). OBJECTIVE: To evaluate International Society of Urological Pathology (ISUP) concordance rates between the final pathology at RP and MRI-TBx or MRI-TBx + random biopsy (RB) according to the biopsy approach. DESIGN, SETTING, AND PARTICIPANTS: A multi-institutional database included patients diagnosed with TP or TR treated with RP. INTERVENTION: TP-TBx or TR-TBx of the prostate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The ISUP grade at biopsy was compared with the final pathology. A multivariable logistic regression analysis (MVA) was performed to assess the association between the biopsy approach (TP-TBx vs TR-TBx) and ISUP upgrading, downgrading, concordance, and clinically relevant increase (CRI). RESULTS AND LIMITATIONS: Overall, 752 (59%) versus 530 (41%) patients underwent TR versus TP. At the MVA, TP-TBx was an independent predictor of upgrading (odds ratio [OR] 0.6, 95% confidence interval [CI] 0.4-0.9, p < 0.01) and improved concordance relative to the final pathology (OR 1.7, 95% CI 1.2-2.5, p < 0.01) after adjusting for age, cT stage, Prostate Imaging Reporting and Data System, number of targeted cores, prostate-specific antigen, and prostate volume. Moreover, TP-TBx was associated with a lower risk of CRI than TR-TBx (OR 0.7, p < 0.01). This held true when considering patients who underwent MRI-TBx + RB (OR 0.6, p < 0.01). The inclusion of men who had RP represents a potential selection bias. CONCLUSIONS: The adoption of TP-TBx compared with TR-TBx may reduce the risk of upgrading and improve the concordance of biopsy grade with the final pathology. The TP approach decreases the odds of CRI with improved patient selection for the correct active treatment. PATIENT SUMMARY: In this report, we evaluated whether transperineal (TP) targeted biopsy (TBx) may improve the concordance of clinically significant prostate cancer with the final pathology in comparison with transrectal (TR) TBx in a large worldwide population. We found that TP-TBx might increase concordance compared with TR-TBx. Adding random biopsies to target one increases accuracy; however, concordance with the final pathology is overall suboptimal even with the TP approach.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Urologia Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Urologia Idioma: En Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Itália